ImmunityBio (formerly NantKwest)

ImmunityBio is a publicly traded biotechnology company, not a private entity run by a single family office. Its leadership includes a CEO and board of directors, but specific investment decision-makers are not publicly named beyond the executive team. The firm does not disclose a CIO or equivalent role.

ImmunityBio is a publicly traded clinical-stage biotechnology company (not a family office). Its primary capital allocation is directed toward R&D and commercialization of its immunotherapy pipeline, rather than external investments. It is part of the NantWorks ecosystem founded by Patrick Soon-Shiong, but that affiliation does not make it a family office.

ANKTIVA is an FDA-approved immunotherapy for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease. It is administered intravesically and activates NK cells, T cells, and macrophages to attack cancer cells while preserving the immune system. The therapy is now marketed in the U.S. and Saudi Arabia.

No. ImmunityBio is a development-stage biopharmaceutical company focused on R&D, clinical trials, and commercialization of its own therapeutics. It does not participate in fund commitments or direct external investments. Its financial activities relate to corporate financing, such as non-dilutive debt and equity offerings.

ImmunityBio's technology is developed internally via its research team and through partnerships. The company's platform is built on activating multiple immune pathways, including NK cells and T cells, using proprietary constructs and adjuvants. Its science is disclosed in SEC filings and academic presentations.

ImmunityBio does not invest; it is a biotech company targeting later-stage clinical development (Phase 2 and Phase 3 trials) and commercialization. Its pipeline includes both early and late-stage programs in bladder cancer, lung cancer, and infectious diseases.

ImmunityBio is a publicly traded company, not a private family office. Its financing comes from public markets, institutional investors, and debt placements. The founding wealth behind its parent entity (NantWorks) is attributed to Patrick Soon-Shiong, a surgeon, inventor, and former owner of pharmaceutical assets, but that wealth is separate from ImmunityBio's capital structure.